–Aspirin remains an established practice for the prevention of another heart attack
or clot-related stroke–

SPARTA, NJ, October 14, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a specialty pharmaceutical company focused on its clinically validated and patent-protected PLxGuard™ drug-delivery platform that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE™ 325-mg and VAZALORE™ 81-mg liquid-filled aspirin capsules (referred to together as “VAZALORE”), today issued a statement on recent United States Preventive Services Task Force (“USPSTF”) recommendations on aspirin therapy for primary prevention of cardiovascular disease.

There has been some confusion regarding recent reports in the media regarding the USPSTF recommended guidelines on the use of aspirin in primary prevention of cardiovascular disease. The draft recommendations issued by the USPSTF pertain to the use of aspirin for the prevention of a first cardiovascular event, and do not pertain to those who have already had a cardiovascular event, such as a heart attack or clot-related stroke and are taking aspirin based on their doctor’s recommendation.

“VAZALORE’s targeted population is those patients with a history of cardiovascular disease and who are already on a physician prescribed aspirin therapy to help prevent another heart attack or clot-related stroke,” said Natasha Giordano, President and CEO of PLx Pharma. “As cardiologists continue to recommend aspirin for their cardiovascular disease patients, VAZALORE is an innovative aspirin with its unique delivery system designed to help protect the stomach. We strongly recommend patients consult with their doctors before starting or stopping aspirin therapy.”

Several years ago, the American College of Cardiology and the American Heart Association updated their recommendations to limit the use of aspirin in patients without established cardiovascular disease. Their recommendations, which are closely followed by cardiologists, state that aspirin is an established practice for the secondary prevention of a heart attack or clot-related stroke.

Millions of people take aspirin daily as part of a physician-prescribed aspirin therapy plan following a heart attack or clot-related stroke. In addition, many patients with a history of gastrointestinal (GI) issues reported discontinuing aspirin therapy against medical advice because of “stomach issues.” VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. The special complex inside the capsule allows for targeted release of aspirin, limiting its direct contact with the stomach. VAZALORE delivers fast, reliable absorption for pain relief plus the lifesaving benefits of aspirin.

# # #

About VAZALORE

VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81-mg and 325-mg doses, that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. The special complex inside the capsule allows for targeted release of aspirin, limiting its direct contact with the stomach. VAZALORE delivers fast, reliable absorption for pain relief plus the lifesaving benefits of aspirin. To learn more about VAZALORE, please visit www.vazalore.com.

About PLx Pharma Inc.

PLx, Pharma, Inc. is a specialty pharmaceutical company focused on improving how active pharmaceutical ingredients (APIs) are absorbed in the gastrointestinal (GI) tract via its clinically validated and patent protected PLxGuard™ drug-delivery platform. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach injury associated with certain drugs. To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

Contact

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com